Our findings suggest that dynamic measurements of CA125 taken during and at the end of chemotherapy treatment for patients with advanced ovarian cancer can identify the patients with a high risk for disease progression and death and, therefore, be used as an intuitive visual tool to monitor a patient’s prognosis. This evidence concerns the gene MUC16 and ovarian carcinoma.